Study: NCT04949256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg once every 6-week-cycle, via IV infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 400 mg once every 6-week-cycle, via IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg once every 6-week-cycle, via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoleucovorin
Description: 200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: 200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.